Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06364163

Effect of Herring Oil Concentrate on LDL Cholesterol Concentration in Adults

A Study on the Effect of Consuming a Herring Oil Concentrate on LDL Cholesterol Concentration in Adults With Overweight or Obesity

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
80 (actual)
Sponsor
University of Bergen · Academic / Other
Sex
All
Age
20 Years – 65 Years
Healthy volunteers
Accepted

Summary

High cholesterol concentration is a major risk factor for cardiovascular disease (CVD), and consumption of fish has been associated with a lower CVD risk in several studies. The beneficial health effects of consuming fish have traditionally been ascribed to the long-chain PUFA (LC-PUFA) EPA (C20:5n-3) and DHA (C22:6n-3), although consumption of fish oils or concentrates with high EPA and DHA contents does not affect the cholesterol concentration in humans and lowers the cholesterol concentration in rats and mice only when given in very high doses. Fish oils contain a plethora of fatty acids besides EPA and DHA, and in recent years, increased focus has been on the long-chain MUFA (LC-MUFA) cetoleic acid (C22:1n-11). Cetoleic acid is found in high amounts in oils from certain fish species such as herring, which has relatively low contents of both EPA and DHA. The investigators have recently summarised and meta-analysed the available literature that investigates the effects of diets containing fish oils or fish oil concentrates that have a high content of cetoleic acid but low or no content of EPA and DHA on cholesterol concentration in rodents, showing that cetoleic acid-rich fish oils and concentrates prevent high cholesterol concentration.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTHerring oil concentrateCapsules containing herring oil concentrate, taken daily for 8 weeks.
DIETARY_SUPPLEMENTControlCapsules containing control oil, taken daily for 8 weeks.

Timeline

Start date
2024-08-12
Primary completion
2026-12-31
Completion
2027-12-31
First posted
2024-04-15
Last updated
2025-10-02

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT06364163. Inclusion in this directory is not an endorsement.